Every 10-Q that ASP Isotopes Inc. (ASPI) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-Q covers the quarterly report filed between annual reports, so if you follow ASPI and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full ASPI filings page.
ASP Isotopes Inc. reported strong top-line growth but continued significant losses for the quarter and six months ended June 30, 2026. Total revenue rose to $9.3 million for the first half of 2026 from $2.3 million a year earlier, driven by specialist isotopes, new U.S. radiopharmacy operations and initial helium and LNG sales from the Renergen acquisition, plus collaboration revenue from TerraPower.
Despite higher revenue and gross profit of $3.1 million, the company posted a loss from continuing operations of $60.7 million for the first half and a net loss attributable to shareholders of $40.5 million, reflecting heavy R&D and selling, general and administrative expenses as it builds out isotope, nuclear fuel and gas projects. Operating cash outflow from continuing operations was $40.0 million, and investing outflow was $57.2 million, including major spending on property, natural gas assets and equity investments.
Liquidity remains substantial, with $219.6 million in cash and cash equivalents and $35.3 million in short-term U.S. Treasury investments as of June 30, 2026. Management states this balance should fund operating and capital needs for more than 12 months, though it anticipates raising additional equity, debt or partnership funding over time. The balance sheet also includes $203.4 million of convertible notes carried at fair value and $192.9 million of natural gas properties from Renergen.
ASP Isotopes Inc. (ASPI) reported sharp growth in early-stage revenue but remains deeply loss-making as it scales new businesses. For the quarter ended March 31, 2026, revenue rose to $4.2 million from $1.1 million a year earlier, driven by nuclear medicine doses and initial LNG and helium sales.
The company posted a $26.7 million net loss from continuing operations, widening from $8.5 million, reflecting higher R&D and selling, general and administrative expenses as it builds enrichment and gas projects. After income from discontinued operations, overall net loss was $7.1 million, or $0.06 per share.
ASPI ended the quarter with $207.3 million in cash and cash equivalents and $83.2 million in short‑term investments, and management believes this will fund operations for more than 12 months. The acquisition of Renergen added natural gas properties and created a new helium and LNG segment, while Skyline’s deconsolidation is now reported as discontinued operations.
ASP Isotopes Inc. (ASPI) reports third-quarter 2025 results reflecting early commercial traction but very heavy losses as it scales its isotope and nuclear fuels platform.
Total revenue reached $4.9 million for the quarter and $7.2 million for the first nine months of 2025, up from $2.95 million a year earlier, driven by both product and new construction services revenue. However, high research and development plus selling, general and administrative costs led to a nine‑month net loss of $96.5 million, compared with $23.2 million in the prior‑year period.
The balance sheet expanded significantly, with cash and cash equivalents of $113.9 million and total assets of $225.9 million as of September 30, 2025, supported by two common stock offerings in June and July 2025 and additional capital raised in October and November. Convertible notes payable at fair value increased to $98.0 million, and total stockholders’ equity rose to $96.6 million.
ASP Isotopes has begun commercial production at two enrichment facilities in South Africa and is preparing initial shipments of enriched C‑12, Si‑28 and C‑14 between late 2025 and the first half of 2026, while also producing Yb‑176 samples. The company is planning additional plants in South Africa, Iceland and the U.S., pursuing a uranium‑235 nuclear fuel initiative, a pending acquisition of Renergen, and a planned spin‑off and U.S. listing of its Quantum Leap Energy (QLE) business, for which a confidential S‑1 has been submitted.